Models to predict non-alcoholic fatty liver disease linked to obesity in Morocco

• Autorzy: Liba H. , Belahsen R.
• Języki publikacji: EN

Abstrakty

EN

Background. The prevalence, risk factors and screening for the problem of non-alcoholic fatty liver disease linked to obesity are not well known in Morocco. The diagnosis of this disease by biopsy is invasive and the assessment of its severity by ultrasound shows variability in observation. Objective. The aim of this retrospective study is to estimate the prevalence of NAFLD linked to obesity, to determine the risk factors associated with it and to develop a non-invasive procedure as a method of diagnosing this disease in Morocco. Material and Methods. It’s a retrospective study. The collection of anthropometric, clinical, biochemical, and radiological data over a period from 2014 to 2018 were captured from registers of patients at the Med VI University Hospital in Marrakech. Data were analyzed using SPSS version 26 software. Descriptive statistics were presented using frequencies and means +/- standard deviation to describe categorical and numeric data respectively. Pearson's chi-square test was used to test the association between categories of two independent samples. Multinomial logistic regression is used to find disease risk factors and models to predict non-alcoholic fatty liver disease (NAFLD) linked to obesity in Morocco. Results. Gender, increased age, body mass index, alanine aminotransferase, triglycerides, C-reactive protein, alkaline phosphatase, gamma-glutamyl transferase were significantly correlated with NAFLD and its evolvement. Conclusion. The prevalence of NAFLD linked to obesity is an alarming problem in Morocco. It was 83.5%. Age, gender, body mass index, alanine aminotransferase, triglycerides, C-reactive protein, alkaline phosphatase and gamma-glutamyl transferase are risk factors for NAFLD and its severity. It were used to develop two algorithms that can be used, as a more objective and non-invasive screening method for NAFLD.

• Wydawca: -
• Czasopismo: Roczniki Państwowego Zakładu Higieny
• Rocznik: 2022
• Tom: 73
• Numer: 3
• Opis fizyczny: p.325-332,ref.

Twórcy

autor

Liba H.

• Laboratory of Biotechnology, Biochemistry and Nutrition, Training and Research Unit on Nutrition and Food Sciences, Faculty of Sciences, Chouaib Doukkali University, El Jadida, Morocco

autor

Belahsen R.

• Training and Research Unit on Nutrition and Food Sciences, Faculty of Sciences, Chouaib Doukkali University, El Jadida, 24000 Morocco

Bibliografia

• 1. García-Compeán D., Villarreal-Pérez JZ., Cavazos MEO., Lavalle-Gonzalez FJ., Borjas-Almaguer OD., Del Cueto-Aguilera AN., González-González JA., Treviño-Garza C., Huerta-Pérez L., Maldonado- Garza HJ.: Prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus. Time for screening? Ann Hepatol 2020;19(3):258-264. doi: 10.1016/j.aohep.2020.01.003
• 2. Younossi ZM., Koenig AB., Abdelatif D., Fazel Y., Henry L., Wymer M.: Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64(1):73-84 oi: 10.1002/hep.28431.
• 3. Andronescu CI., Purcarea MR., Babes PA.: Nonalcoholic fatty liver disease: epidemiology, pathogenesis and therapeutic implications. J Med Life 2018;11(1):20-23.
• 4. Castera L., Friedrich-Rust M., Loomba Castera R.: Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2019;156(5):1264-1281 doi: 10.1053/jgastro 2018; 12.036.5.
• 5. Shannon A., Alkhouri N., Carter-Kent C., Monti L., Devito R., Lopez R., Feldstein AE., Nobili V.: Ultrasonographic quantitative estimation of hepatic steatosis in children With NAFLD. J Pediatr Gastroenterol Nutr 2011;53(2):190-5 doi: 10.1097/MPG.0b013e31821b4b61
• 6. Jennison E., Patel J., Scorletti E., Byrne CD.: Diagnosis and management of non-alcoholic fatty liver disease. Postgrad Med J. 2019;95(1124):314-322 doi: 10.1136/postgradmedj-2018-136316.
• 7. Loomba R., Cui J., Wolfson T., Haufe W., Hooker J., Szeverenyi N., Ang B., Bhatt A., Wang K., Aryafar H., Behling C., Valasek MA., Lin GY., Gamst A., Brenner DA., Yin M., Glaser KJ., Ehman RL., Sirlin CB.: Novel 3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD: A Prospective Study. Am J Gastroenterol 2016;111(7):986-94 doi: 10.1038/ajg.2016.65.
• 8. Park CC., Nguyen P., Hernandez C., Bettencourt R., Ramirez K., Fortney L., Hooker J., Sy E., Savides MT., Alquiraish MH., Valasek MA., Rizo E., Richards L., Brenner D., Sirlin CB., Loomba R.: Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease. Gastroenterology 2017;152(3):598-607 doi: 10.1053/j.gastro.2016.10.026.
• 9. Godoy-Matos AF., Silva Júnior WS., Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr 2020;12:60 doi: 10.1186/s13098-020-00570-y.
• 10. Pappachan JM., Babu S., Krishnan B., Ravindran NC. Non-alcoholic Fatty Liver Disease: A Clinical Update. J Clin Transl Hepatol 2017;5(4):384-393 doi: 10.14218/JCTH.2017.00013.
• 11. Anderson EL., Howe LD., Jones HE., Higgins JP., Lawlor DA., Fraser A. The Prevalence of Non- Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis. PLoS One 2015;10(10):e0140908; doi: 10.1371/journal. pone.0140908.
• 12. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organization. Tech Rep Ser. 2000; 894: i-xii., 1-253.
• 13. World Health Organization. [Report of the National Survey on Common Risk Factors for Non-Communicable Diseases Morocco (2017 – 2018)]. 2019.
• 14. Habiba L., Mohamed M., Rekia., B.: Non-alcoholic fatty liver disease in Morocco: The situation., the determinants and the challenges for health care. World Journal of Advanced Research and Reviews 2020; 6(1).,207-217doi: 10.30574/wjarr.2020.6.1.0100
• 15. Belahsen R., Mziwira M., Fertat F. Anthropometry of women of childbearing age in Morocco: body composition and prevalence of overweight and obesity. Public Health Nutr. 2004;7(4):523-30 doi: 10.1079/PHN2003570.
• 16. World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens1999; 17(2):151-83.
• 17. Anwar S., Rashid H., Aleem B., Moslhey G- J., Al Rashdi A- S.: Correlation between anthropometric measurements and hypertension in Oman. Age (years) 2020; 48(1).53. 42.36-0.97.
• 18. American Diabetes Association. Executive summary: Standards of medical care in diabetes2012. Diabetes Care 2012; 35:S4-S10 doi: 10.2337/dc12-s004.
• 19. Baudin., B.: Biochemical exploration of the liver in 2017. Francophone Journal of Laboratories 2017(490):25-33.
• 20. Younossi ZM.: Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol 2019;70(3):531-544; doi: 10.1016/j.jhep.2018.10.033.
• 21. Dixon JB., Bhathal PS., O’Brien PE.: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121(1):91-100 doi: 10.1053/gast.2001.25540.
• 22. Vanni E., Bugianesi E., Kotronen A., De Minicis S., Yki-Järvinen H., Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010;42(5):320-30. doi: 10.1016/j.dld.2010.01.016.
• 23. López-Velázquez JA., Silva-Vidal KV., Ponciano-Rodríguez G., Chávez-Tapia NC., Arrese M., Uribe M., Méndez-Sánchez N.: The prevalence of nonalcoholic fatty liver disease in the Americas. Ann Hepatol. 2014;13(2):166-78; https://doi.org/10.1016/S1665-2681(19)30879-8
• 24. Estes C., Anstee QM., Arias-Loste MT., Bantel H., Bellentani S., Caballeria J., Colombo M., Craxi A., Crespo J., Day CP., Eguchi Y., Geier A., Kondili LA., Kroy DC., Lazarus JV., Loomba R., Manns MP., Marchesini G., Nakajima A., Negro F., Petta S., Ratziu V., Romero- Gomez M., Sanyal A., Schattenberg JM., Tacke F., Tanaka J., Trautwein C., Wei L., Zeuzem S., Razavi H.: Modeling NAFLD disease burden in China., France., Germany., Italy., Japan., Spain., United Kingdom., and United States for the period 2016-2030. J Hepatol 2018; 69(4):896-904 doi: 10.1016/j.jhep.2018.05.036.
• 25. Goossens N., Bellentani S., Cerny A., Dufour JF., Jornayvaz FR., Mertens J., Moriggia A., Muellhaupt B., Negro F., Razavi H., Semela D., Estes C.: Nonalcoholic fatty liver disease burden - Switzerland 2018-2030 Swiss Med Wkly 2019;149:w20152 doi: 10.4414/smw.2019.20152.

Identyfikatory

DOI

10.32394/rpzh.2022.0223